Boan Biotech (6955.HK) announced its 2022 financial results and recent business developments on March 27, 2023.2022 business highlightsRecord high in revenueIn 2022, Boan Biotech's revenue was app...
Yantai, China, March 21, 2023 —Luye Pharma Group today announced that the Biologics License Application (BLA) for BA1102 (Denosumab Injection), a biosimilar for the oncology indications developed by ...
Boan Biotech today announced that patient enrollment has been completed for the Phase 3 clinical study (comparative clinical study of efficacy and safety) of BA9101 (Aflibercept Intravitreous Injectio...
Shanghai, February 23, 2023 - Luye Pharma Group today announced that it has received the approval by the competent authorities to initiate the first clinical trial in Europe for its Paliperidone Palmi...
Rykindo® is a bi-weekly long-acting risperidone injection and is the first innovative therapy from Luye Pharma’s Central Nervous System (CNS) product portfolio to be marketed in the United State...
January 9, 2023 – Luye Pharma Group today announced the launch of the Named Patient Program (NPP) in Hong Kong, China, providing eligible local patients immediate access to the innovative anti-c...
January 09, 2023 - Luye Pharma Group announced today that BA1301 for injection, an innovative antibody-drug conjugate (ADC) candidate developed by its subsidiary Boan Biotech, has been approved for cl...
(30 December 2022, Hong Kong, China)Shandong Boan Biotechnology Co., Ltd. (“Boan Biotech” or the “Company”), a subsidiary of Luye Pharma Group, was officially listed on the Main Board of the Stock...
November 21, 2022 - Luye Pharma Group announced today that a pivotal study conducted in the U.S. for the company's in-house developed innovative formulation, Paliperidone Palmitate Extended-releas...
Luye Pharma Group today announced that Denosumab Injection (Boyoubei®) developed by its subsidiary Boan Biotech has been approved for launch in China by the National Medical Products Administration (N...
TOP